300
Participants
Start Date
June 10, 2024
Primary Completion Date
November 30, 2025
Study Completion Date
December 31, 2025
INDV-2000
INDV-2000 is a highly potent and selective OX1R antagonist that is being developed as a therapy for the treatment of OUD.
Placebo
This is a randomized, double-blind, placebo-controlled study.
Richmond Behavioral Associates, Staten Island
Dr Vando Medical Services, The Bronx
Maryland Treatment Centers, Baltimore
Monroe Biomedical Research, Monroe
West Clinical Research, Morehead City
Prisma Health Addiction Medicine Center, Greenville
Agile Clinical Research Trials, Atlanta
Bold City Clinical Research, Jacksonville
Segal Trials Miami Lakes, Miami Lakes
Clinical Research Center of Florida, Pompano Beach
Quantum Clinical Trials, Miami Beach
Imagine Research of Palm Beach County, Boynton Beach
Accel Research Sites - Lakeland, Lakeland
Vitalix Kissimmee, Kissimmee
Boyett Health Services Inc, Hamilton
Precise Research Centers, Flowood
Midwest Clinical Research Center, LLC, Dayton
Insight Research Institute, Flint
Arch Clinical Trials, St Louis
Pahl Pharmaceutical Professionals, LLC, Oklahoma City
SP Research PLLC Rivus Wellness and Research Insitute, Oklahoma City
Unity Clinical Research, Oklahoma City
Insite Clinical Research, LLC, DeSoto
HD Research, Houston
El Paso Clinical Trials, El Paso
Progressive Clinical Research Llc, Bountiful
Alpine Research Organisation, Clinton
Boeson Clinical Research, Provo
Elite Clinical Studies, LLC, Phoenix
IMA Clinical Research, Las Vegas
Oasis Clinical Research, Las Vegas
Empire Clinical Research, Pomona
North County Clinical Research, Oceanside
Artemis Institute For Clinical Research - San Diego, San Diego
Vitalix Clinical, Worcester
Lead Sponsor
Indivior Inc.
INDUSTRY